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Abstract
Safety assessment in drug development involves numerous statistical challenges,
and yet statistical methodologies and their applications to safety data have not
been fully developed, despite a recent increase of interest in this area. In practice,
a conventional univariate approach for analysis of safety data involves application
of the Fisher’s exact test to compare the proportion of subjects who experience
adverse events (AEs) between treatment groups; This approach ignores several
common features of safety data, including the presence of multiple endpoints, lon-
gitudinal follow-up, and a possible relationship between the AEs within body sys-
tems. In this article, we propose various regression modeling strategies to model
multiple longitudinal AEs that are biologically classified into different body sys-
tems via the stratified quasi-least squares (SQLS) method. We then analyze safety
data from a clinical drug development program at Wyeth Research that compared
an experimental drug with a standard treatment using SQLS, which could be a
superior alternative to application of the Fisher’s exact test.
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Summary: Safety assessment in drug development involves numerous statistical challenges, and yet
statistical methodologies and their applications to safety data have not been fully developed, despite
a recent increase of interest in this area. In practice, a conventional univariate approach for analysis of
safety data involves application of the Fisher’s exact test to compare the proportion of subjects who
experience adverse events (AEs) between treatment groups; This approach ignores several common
features of safety data, including the presence of multiple endpoints, longitudinal follow-up, and
a possible relationship between the AEs within body systems. In this article, we propose various
regression modeling strategies to model multiple longitudinal AEs that are biologically classified into
different body systems via the stratified quasi-least squares (SQLS) method. We then analyze safety
data from a clinical drug development program at Wyeth Research that compared an experimental
drug with a standard treatment using SQLS, which could be a superior alternative to application of
the Fisher’s exact test.
Key words: Longitudinal Data; Adverse Events; Drug Safety; Generalized Estimating Equations;
Stratified Quasi-least Squares; Multiple Sources of Correlation.
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1. Introduction
In the area of pharmaceutical drug safety, one of the primary goals in the analysis of
adverse events (AEs) is to detect any signal for a difference between the treatment versus
control arms with respect to the development of AEs. A simple and perhaps one of the
most popular approaches for analysis of AEs is to compare the proportion of subjects who
experience AEs between the treatment and control arms using the Fisher exact test; This
involves constructing a dichotomous variable for each AE that takes value 1 for subjects
who experienced that AE, and that takes value 0 otherwise. Next, at a nominal 5% level
of significance, if the computed Fisher’s exact p-value for each AE is greater than 0.05, the
typical conclusion is that the Fisher’s exact tests have provided no strong evidence, or signal,
that the rate of AEs differs between treatment arms. (See Table 1 of Mehrota and Heyse
(2004) for an example.)
Safety data, however, are often multi-dimensional, due to the fact that multiple AEs are
typically assessed on subjects over time. As a result, a multivariate approach could be
employed to detect signals in the differences between the treatment and control arms with
respect to the development of AEs. Furthermore, popular approaches that reduce information
on each AE to a dichotomous variable prior to the implementation of a univariate method
such as application of the Fisher’s exact test, may result in a substantial loss of information
(by overly simplifying the original multi-dimensional structure of the data) which may
jeopardize the validity of the statistical conclusions.
In practice, AEs are often recorded by self-report from study participants and/or investi-
gators during scheduled visits, in which participants may report that they have experienced
multiple AEs of different types since their prior visit. Reported AEs will then typically
be classified in terms of affected body systems in accordance with accepted dictionaries
of preferred AE vocabulary such as COSTART (Chow and Liu, 2003, p563) and Med-
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2DRA (MedDRA, 2004). For example, some of the preferred terms for body systems in
the COSTART dictionary include the digestive, nervous, metabolic and nutritional, and
respiratory systems. Each body system in COSTART has its own distinct set of AEs that
are described using the COSTART preferred terminology, e.g. the AEs associated with the
digestive system include vomiting, nausea, diarrhea, and constipation.
Despite a recent increase in interest and attention paid to the issue of pharmaceutical drug
safety, few methods are available that propose either the novel implementation of existing
methods, or new statistical methodologies, for analysis of safety data. One recent approach
addresses the issue of multiplicity using a three-level Bayesian hierarchical mixture model to
directly calculate the posterior probability that the (random) log odds ratio for development
of AEs between the treatment and control groups is greater than one (Berry and Berry, 2004);
These authors considered three types of AEs that had been identified by Mehrota and Heyse
(2004). Goldberg-Alberts and Page (2006) fit a log-linear model to the total number of AEs
in order to explore the strength of association between multiple AEs. In addition, Schildcrout
et. al. (2008) focused on modeling longitudinal clinical laboratory data in the presence of
dropout, follow-up frequency, and treatment discontinuation, based on both the generalized
estimating equation (Liang and Zeger, 1986) and maximum likelihood approaches. Each of
the methods just cited addresses different issues in the analysis of drug safety data that
represent important and meaningful first steps toward a clearer understanding of the issues
involved in and optimum approaches for analysis of safety data.
In this paper, we make an additional contribution to the relatively open field of analysis
of safety data. We are mainly concerned with a modeling strategy for the analysis of AEs
by incorporating multiple sources of correlation (that result from the fact that multiple
AEs are measured on subjects over time) using our proposed method, stratified quasi-least
squares (SQLS). SQLS generalizes the method of quasi-least squares (QLS) (Chaganty and
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Shults, 1999), a two-stage approach for analysis of longitudinal data with an assumed working
correlation structure in the framework of generalized estimating equations (GEE) (Liang and
Zeger, 1986).
Prior to the development of SQLS, QLS had been extended for analysis of longitudinal data
with multiple outcomes, but this prior extension was limited to either totally balanced data
for two sources of correlation (Chaganty and Naik, 2002), or data with two or more sources of
correlation that were balanced within subjects (Shults and Morrow, 2002; Shults, Whitt and
Kumanyika, 2004; Shults and Ratcliffe, 2007). For example, Table 1 displays a data structure
for multi-outcome longitudinal data, for which up to three outcomes were measured on each
cluster i at a total of 5 measurement occasions. If we consider only measurements from
cluster 1, then the data are totally balanced because 5 measurements were collected on each
of 3 outcomes. Next, if we consider measurements from clusters 3 and n only, then the data
are balanced within subjects because the same number of measurements was collected on
all measured outcomes within each cluster. Finally, if we consider only measurements from
cluster 2, then the data are unbalanced because the number of measurements varied between
outcomes for this cluster.
Prior approaches that extended QLS for analysis of data with multiple sources of corre-
lation (Shults and Morrow, 2002; Chaganty and Naik, 2002; Shults, Whitt and Kumanyika,
2004; Shults and Ratcliffe, 2007) described the pattern of association amongst multiple
longitudinal outcomes by specifying a working correlation structure that was constructed
as the Kronecker product of correlation structures that would be appropriate for each source
of correlation, if that were the only source of correlation in the data. For example, for analysis
of multiple outcomes that are measured over time, a plausible working correlation structure
would be the Kronecker product of an exchangeable correlation structure (for the multiple
http://biostats.bepress.com/upennbiostat/art29
4Table 1
Example of data format for longitudinal data with 3 outcomes at 5 time points
Cluster Outcome Time Points
i j 1 2 3 4 5
1 y111 y112 y113 y114 y115
1 2 y121 y122 y123 y124 y125
3 y131 y132 y133 y134 y135
1 y211 · y213 y214 y215
2 2 y221 y222 y223 y224 y225
3 y231 · y233 · y235
1 y311 y312 y313 y314 ·
3 2 y321 y322 y323 y324 ·
3 y331 y332 y333 y334 ·
...
...
...
1 yn11 yn12 yn13 yn14 yn15
n 2 · · · · ·
3 yn31 yn32 yn33 yn34 yn35
· represents missing observation.
outcomes) and a first-order autoregressive (AR1) structure (for the outcomes over time).
SQLS extends these prior approaches for analysis of unbalanced data by assuming that the
working correlation structure for each subject is a sub-matrix of a larger Kronecker product
structure; This assumption is appropriate for studies that planned for balanced data, but for
which some measurements were missing.
Unbalanced data are common in safety studies. For example, the following situations led
to unbalanced safety data in the Depression Research Unit (DRU) at the University of
Pennsylvania (Dr. Jay Amsterdam, Head of DRU, personal correspondence): Investigators
who were embarrassed to ask about sexual side effects of depression had missing data for this
type of AE. In a study of SSRI anti-depressants, information was collected on gastrointestinal
AEs, but no information was obtained regarding gynecomastia (breast enlargement) due to
sensitivity on the part of investigators to ask about this condition; Furthermore, no patients
volunteered information on this condition. In some studies, information was missed due
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to confusion regarding the difference between illness symptoms (e.g. decreased libido as a
symptom of depression) versus AE (e.g. erectile dsyfunction as a result of medication).
In addition to extending QLS for analysis of unbalanced data with multiple sources of
correlation, SQLS also allows for construction of working correlation structures that are
stratified according to a third variable of interest. For example, for analysis of multiple AEs
that are measured over time, as mentioned above, a plausible working correlation structure is
Exchangeable(ρ)⊗AR1(α), where ⊗ represents the Kronecker product, and ρ and α represent
the correlations parameters for the exchangeable and AR1 structures, respectively. However,
each body system has a distinct set of AEs, so that fitting a common exchangeable structure
for all AEs may not be a reasonable choice. For example, although it might be reasonable to
assume that the pairwise correlations between AEs are the same within each body system, we
might anticipate a greater degree of similarity of occurrence of AEs within some body systems
in comparison with others. SQLS therefore allows the parameters for the exchangeable
structure to vary according to body system, so that the exchangeable structure for multiple
AEs is the exchangeable(ρj) for the jth body system.
Our outline for the manuscript is as follows. In §2, we describe our motivating example
from a study of safety data from a clinical drug development program at Wyeth Research.
In §3 we then describe our development of SQLS for the analysis of the AE data introduced
in §2. In §4 we next analyze the AEs data via SQLS. Finally, we provide a brief discussion
and some concluding remarks in §5.
http://biostats.bepress.com/upennbiostat/art29
62. Wyeth Safety Data
Our goal in this report is to describe our approach to the analysis of safety data and to
demonstrate the potential approach. Safety data from positive controls were obtained from
a clinical drug development program at Wyeth. Data were blinded to the drug, adverse
event, and body system. Simulation was used to produce an adverse event profile for an
hypothetical comparator drug in order to evaluate the potential approach to analysis.
Table 2
Example of 15 selected adverse events from the Wyeth control data set. AEij represents the j
th adverse event in the
ith body system. Rates were computed by dividing the total number of subjects who experienced AEij by 412, the
number of subjects at the start of the trial.
Body System AEij Y
∗
ij Rates
1 AE11 81 0.197
1 AE12 112 0.272
1 AE13 84 0.204
1 AE14 11 0.027
1 AE15 3 0.022
1 AE16 9 0.002
1 AE17 1 0.007
1 AE18 3 0.009
2 AE21 49 0.119
2 AE22 80 0.194
2 AE23 21 0.051
2 AE24 7 0.017
2 AE25 8 0.019
2 AE26 18 0.044
2 AE27 1 0.002
* Total number of subjects who experienced AEij .
The Wyeth safety study involved 5 weekly scheduled visits for each participant. The first
two weeks corresponded to the on-therapy period and the remaining weeks corresponded
to the follow-up period. The durations of AEs were recorded either during the physical
examination and clinical evaluation of a subject during his/her scheduled visit, or through
a self-report from the subject. Table 2 displays the total number of subjects (out of 412
subjects in the control arm at the start of the trial) who had experienced an adverse event
among 15 selected AEs (8 AEs for body system 1 and 7 AEs for body system 2).
One challenging issue in the analysis of safety data is the low frequency of occurrence
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of some AEs. For example, in Table 2, the rate for all AEs is below 6%, except for AE11,
AE12, AE13, AE21, and AE22. Rare AEs are often investigated on a case by case basis by the
study clinician(s), as opposed to making a formal statistical comparison. For example, one
case of headache in the treatment group versus zero headaches in the control group might
be simply described in the report of safety data. In this paper, we focused on AEs that
occurred frequently enough to warrant a formal statistical comparison. We considered AEs
that occurred in at least 10 percent of study participants, although admittedly a different
threshold could have been applied.
3. Stratified Quasi-least Squares
3.1 General Setup and Notation
We let yijkl represent the kth outcome (AE), in the jth stratum (body system), at the lth
time, for the ith cluster (subject), where i = 1, . . . , nj, j = 1, . . . , g, k = 1, . . . , nij, and
l = 1, . . . , nijk. Let yijk be a nijk × 1 vector of the kth outcome in the jth stratum such that
yijk = (yijk1, yijk2, . . . , yijknijk)
′. Further, let yij = (y′ij1, y
′
ij2, . . . , y
′
ijnij
)′, i.e. yij is the vector
of outcomes in the jth strata for the ith cluster that has been sorted according to indices k
followed by l. For example, for nij = 2, nij1 = 3, and nij2 = 4,
yij = (yij11, yij12, yij13, yij21, yij22, yij23, yij24)
′. (1)
We assume that the outcomes yijkl have mean and variance given by E(yijkl) = µijkl and
Var(yijkl) = φh(µijkl) respectively, where φ > 0 is a known or unknown scale (dispersion)
parameter and h(·) is the variance function. We also assume that each yijkl is associated
with a vector of covariates xijkl = (xijkl1, . . . , xijklp)
′ and unknown regression parameters
β = (β1, . . . , βp) through an invertible link function g(·) such that µijkl = g−1(x′ijklβ).
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8Next, let zijkl = (yijkl − µijkl) /
√
h(µijkl) represent the Pearson residual that corresponds
to yijkl. Let zijk be the vector of Pearson residuals for each AE k = 1, . . . , nij for the jth
stratum, and let
zij = (z
′
ij1, z
′
ij2, . . . , z
′
ijnij
)′, (2)
be the vector of Pearson residuals that has been sorted by index k followed by l for the ith
cluster in the jth stratum.
We further assume that measurements from two different vectors yij (i.e. from different
body systems on subjects) will be independent, but that measurements within vectors yij
(i.e. within body systems) will be correlated, due to similarity among the multiple AEs at
each measurement occasion, and across time points. (Note that if we do not stratify on body
system, then we will not need to assume independence across body systems.) As in GEE,
we decompose the covariance matrix of yij as
Σij = φA
1/2
ij Rij(ρj, α)A
1/2
ij (3)
where Aij = diag(h(µij11), . . . , h(µijnijnijk)), and Rij(ρj, α) is known as the working corre-
lation matrix that describes the pattern of association among the repeated measurements
on each subject i for stratum j. We further decompose Rij(ρj, α) = Rij(ρj)⊗ Ri(α), where
Rij(ρj) is our reasonable guess of the true correlation structure to describe the pattern
of association between the multiple AEs in stratum j at each measurement occasion, and
Ri(α) is our reasonable guess of the common correlation structure to describe the pattern of
association amongst the repeated AE measurements over time.
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3.2 SQLS for Unbalanced Longitudinal Data with Multiple Outcomes
The KP correlation structure in (3) is a popular choice for analysis of multi-outcome lon-
gitudinal data because it forces the correlation between measurements to be smaller when
they have more disagreement with respect to the sources of correlation in the data, which is
often biologically plausible in longitudinal studies. For example, the KP structure has been
implemented for analysis of Gaussian data by Galecki (1994), Lu and Zimmerman (2005),
Naik and Rao (2001), Roy and Khattree (2005), Roy (2006), and Roy and Leiva (2007).
Moreover, the Kronecker product has convenient mathematical properties, in particular a
simple expression for its inverse. However, for unbalanced data, the working correlation
structure can no longer be expressed as a KP structure. As a result, the correlation structures
for unbalanced data lose mathematical tractability, which is why previous implementations
of QLS for multi-outcome longitudinal data focused on balanced data. (For example, Shults,
Whitt and Kumanyika (2004) presented a straightforward algorithm for implementation of
a KP structure for QLS that utilized the square root of the inverse of the KP structure.)
Here we introduce an alternative way to express the working correlation structure so that
it is a function of the KP structure, even for unbalanced data. Our approach will hinge on
considering a study that planned for balanced data, with a KP structure to describe the
pattern of multiple AEs over time amongst subjects with complete data. The correlation
structure of subjects with missing measurements will then a sub-matrix of the larger KP
structure, that has been constructed by removing rows and columns from the larger KP
matrix that correspond to the missing measurements.
To formalize this discussion, we first consider positive definite and symmetric matrices
Rj(ρj) and R(α) of dimensions mj ×mj and m×m respectively, where mj is the maximum
http://biostats.bepress.com/upennbiostat/art29
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number of types of outcomes across all clusters in the jth stratum, and m is the maximum
number of time points across all clusters and strata. Then it is well known that Rj(ρj)⊗R(α)
is also a positive definite and symmetric matrix of dimension mjm×mjm. Next, let W be the
matrix that is constructed by removing the jth row and the jth column of the Rj(ρj)⊗R(α)
matrix. Using the following argument, it is also easy to show that W is positive definite: For
a non-zero vector x of the same dimension as W , we have that x′Wx = y′(Rj(ρj)⊗ R(α))y
where y is the vector x, but with a zero replaced in the jth position in x. Since y 6= 0 and
Rj(ρj)⊗R(α) is positive definite, it follows that
x′Wx = y′(Rj(ρj)⊗R(α))y > 0. (4)
Therefore, W is positive definite.
Next, let Kj be the set of all indices jkl such that
Kj = {j11, . . . , j1m, j21, . . . , j2m, . . . , jmj1, . . . , jmjm}.
Further, let Iij = {jkl : jkl /∈ Kj} for each cluster i in the jth stratum, i.e. Iij denotes
the missing indices for the ith cluster in the jth stratum that are not contained in the
overall index set Kj. Denote eijkl as the mjm× 1 elementary vector with a one in the jklth
row and zeros elsewhere. Next, let Ei be an mjm × (mjm − card(Iij)) matrix defined as
Ei = (eij11, eij12, . . . , e1jmjm) for all jkl ∈ Kj \ Iij, where card(Iij) denotes the number of
elements in the set Iij. For example, suppose the maximum number of types of outcomes
and time points across all subjects are 2 and 4 respectively, i.e. mj = 2, and m = 4. Then
Kj = {j11, j12, j13, j14, j21, j22, j23, j24}. If the jth stratum in the ith cluster has a missing
observation in the 2nd outcome at the 3rd time point, i.e. yij23 is not observed, then
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Eij =

1 0 0 0 0 0 0
0 1 0 0 0 0 0
0 0 1 0 0 0 0
0 0 0 1 0 0 0
0 0 0 0 1 0 0
0 0 0 0 0 1 0
0 0 0 0 0 0 0
0 0 0 0 0 0 1

8×7
where each column vector corresponds to eij11, eij12, eij13, eij14, eij21, eij22, and eij24, re-
spectively. Note that the 7th observation yi123 was missing, so that Eij was constructed
by removing the 7th column of an 8 × 8 identity matrix. Finally, let Wij be the matrix
that is constructed by removing any missing rows and their corresponding columns of the
Rij(ρj)⊗Ri(α) matrix. Then it is easy to verify that
Wij = E
′
ij(Rj(ρj)⊗R(α))Eij (5)
which is a positive definite and symmetric matrix by (4). That Wij is invertible which follows
from the fact that this matrix is positive definite. However, the inverse will not have a simple
expression when Eij is not an identity matrix, i.e. when the data are unbalanced.
3.3 Stratified Quasi-least Squares
GEE estimates the correlation parameters via the method of moments. SQLS (and QLS),
on the other hand, is a two-stage approach that estimates correlation parameters using
estimating equations that are orthogonal to the estimating equation for β. One advantage
of SQLS is that it is straightforward to apply, even for a relatively complex correlation
structure.
For estimating β, SQLS solves the following estimating equation at given values of α and
http://biostats.bepress.com/upennbiostat/art29
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ρj for j = 1, . . . , g: ∑
i,j
(
∂µij
∂β
)′
A
−1/2
ij W
−1
ij A
−1/2
i (yij − µij) = 0 (6)
where Wij is given in (5).
Stage one estimating equations for α and ρj are obtained by taking the partial deriva-
tives with respect to α and ρj respectively in the generalized error sum of squares: Q =∑
i,j z
′
ijW
−1
ij zij, where zij is the vector of Pearson residuals defined in (2). Thus, the stage 1
estimating equations for α are given by
∂Q
∂α
=
∂
∂α
{∑
i,j
z′ijW
−1
ij zij
}
=
∑
i,j
z′ijW
−1
ij (α)
∂Wij
∂α
W−1ij (α)zij
= −
∑
i,j
z′ijWij
[
E ′ij
(
Ri(ρi)⊗ ∂R(α)
∂α
)
E ′ij
]
Wijzij
= 0,
(7)
where the third equality follows from that fact that
∂W−1ij
∂α
= −W−1ij
∂Wij
∂α
W−1ij (8)
for any α such that Wij is positive definite. Similarly, the stage 1 estimating equation for ρj
is given by
∂Q
∂ρj
=
nj∑
i=1
z′ijWij
[
E ′ij
(
∂Rj(ρj)
∂ρj
⊗R(α)
)
E ′ij
]
Wijzij = 0, (9)
for j = 1, . . . , g, using (8). It is important to note that the summation in the stage 1
estimating equation for α ranges from i = 1, . . . , nj for all strata j = 1, . . . , g, whereas the
summation for ρj ranges from i = 1, . . . , nj.
SQLS alternates between solving the GEE estimating equation (6) and the stage 1 esti-
mating equations (7, 9) until there is convergence in the estimates. However, the stage 1
estimates for α and ρj are asymptotically biased. Bias correction is made via the stage 2
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estimating equations to obtain consistent estimates for α and ρj, i = 1, . . . , g. (See Chaganty
and Shults (1999) Theorem 3.2). The stage 2 estimating equations for this bias correction
are given by
∑
i,j
tr
{
∂W˜−1ij
∂α˜
Wij
}
= 0 and
nj∑
i=1
tr
{
∂W˜−1ij
∂ρ˜j
Wij
}
= 0 (10)
for α and ρj, respectively, where “tr” is the trace, and W˜ij is the Wij matrix evaluated at
the stage 1 estimates α˜ and ρ˜j, j = 1, . . . , g.
SQLS then alternates between solving the GEE estimating equation (6) and the stage 2
estimating equations (10), in order to obtain the final estimates for β, α and ρj, j = 1, . . . , g.
Using (8), the stage 2 estimating equations for α and ρj, j = 1, . . . , g are given by
∑
i,j
tr
(
W˜ij
[
E ′ij
(
Rj(ρ˜j)⊗ ∂R(α˜)
∂α˜
)
Eij
]
W˜ijRi(α)
)
= 0 (11)
and
nj∑
i=1
tr
(
W˜ij
[
E ′ij
(
∂Rj(ρ˜j)
∂ρ˜j
⊗R(α˜)
)
Eij
]
W˜ijRij(ρj)
)
= 0, (12)
respectively.
3.4 Estimates of the Covariance Matrix in SQLS
As in GEE, SQLS also implements the so-called sandwich estimate of the covariance matrix
which uses the empirical evidence from the data to adjust the standard errors. The sandwich
estimator is popular due to the consistency of the regression parameter βˆ even under a
misspecification of the true correlation structure under mild regularity assumptions (Liang
and Zeger, 1986). The sandwich estimate of the covariance matrix in SQLS is given by
Ĉov(βˆ) = V −1
{∑
i,j
X ′ijA
1/2
i Wˆ
−1
ij zˆij zˆ
′
ijWˆ
−1
ij A
1/2
i Xij
}
V −1
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Figure 1. Number of AEs with rates greater than 10% in Table 2. AEs in the treatment
arm were simulated based on the control arm using a mixture of Poisson and Bernoulli
random variables.
where
V =
∑
i,j
X ′ijA
1/2
ij Wˆ
−1
ij A
1/2
ij Xij,
Wˆij = W (ρˆj, αˆ), zˆij = zij(βˆ), and Xij is the design matrix for the ith cluster in the jth
stratum.
4. Analysis of the Wyeth Safety Data
Table 2 summarizes the total proportion of subjects who experienced AEs in body systems
1 and 2. However, a more informative way to present the Wyeth safety data might be to
summarize the total number of AEs per subject, during each week of follow up. Figure 1
displays information on the AEs with rates greater than 10% from Table 2, i.e. AE11, AE12,
AE13, AE21, and AE22, and for the simulated treatment data. The total number of AEs were
calculated based on the total number of days for which a subject experienced AEij during
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each week. For example, if a subject experienced AE11 for two consecutive days during the
first week, we considered the total number of AEs for AE11 on this subject to be 2.
The number of AEs for the treatment data were simulated based on the control data using
a mixture of Poisson and Bernoulli random variables. Let yijkl be the kth AE in the jth body
system at the lth visit for the ith subject, where i = 1, . . . , nj, j = 1, . . . , g, k = 1, . . . , nij,
and l = 1, . . . , nijk. For the treatment arm, define
yijkl =
{
yijkl + xI0.2 for the on-therapy period, i.e. l 6 2
yijkl + xI0.1 for the follow-up period, i.e. l > 2
where x is the Poisson random variable with mean 0.5, and Ip = 1 with probability p;
otherwise 0 with probability 1 − p, 0 < p < 1. We therefore added the Poisson random
variable with mean 0.5 to a randomly selected portion of the control data. For the on-therapy
period, 20% of the control data were randomly selected, and for the follow-up period, only
10% of the control data were randomly selected.
From Figure 1, it is readily seen that the number of AEs for the treatment arm is greater
than for the control arm for all AE types. However, for AE21 and AE22, subjects in the
treatment arm experienced more AEs during the on-therapy period than during the follow-up
period. On the other hand, the opposite may be true for AE11, i.e. subjects in the treatment
arm experienced more AEs during the follow-up period than during the on-therapy period.
Table 3 summarizes the Fisher’s exact p-values for comparing the proportions of each
AEij for the control and the treatment arms. None of the AEs were significant at a nominal
5% significance level, which suggests that there was no strong signal for a difference in
the proportion of subjects who had adverse event AEij between the two treatment groups.
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However, for AE11 and AE21, the p-values ≈ 0.06, which might warrant some additional
investigation.
Table 3
Two-sided Fisher’s exact p-values for AE11, AE12, AE13, AE21, and AE22. Rates are calculated by the total number
of subjects who experienced AEij over 412, the total number of subjects at the start of the trial for both arms. Yij
and Xij are the total number of subjects who experienced AEij for the control and the treatment arms respectively.
Control Treatment Fisher’s
AEij Y
†
ij Rate X
‡
ij Rate exact p-value
AE11 81 0.1966 104 0.2524 0.0661
AE12 112 0.2718 125 0.3034 0.3557
AE13 84 0.2039 100 0.2427 0.2095
AE21 49 0.1189 69 0.1675 0.0585
AE22 80 0.1942 86 0.2087 0.6642
A more sophisticated analysis which leads to a better understanding of the AE data may
be accomplished via the method of SQLS using the Exchangeable(ρj)⊗AR1(α) structure for
which we allow different parameters ρj for multiple AEs within each body system j, and a
common parameter α for the correlation over time.
Recall that the primary goal of the analysis is to detect any signal that there is a difference
in the two arms with respect to the AEs. We will consider several regression models in a
sequential fashion to accomplish our analytic goal. First, we consider a model to compare
the overall differences in the number of AEs per subject, given by
log(µijkl) = β0 + β1trti (13)
where µijkl is the mean of the Poisson random variable, and trti = 1 if the ith subject is in
the treatment group; and = 0 otherwise. After fitting Model (13), we may consider a model
with two-way interaction terms between each type of AE and trti, for testing a difference in
the number of AEij between the control and the treatment arms. This model is given by
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Table 4
Summary of the model fit for models (13), (14), and (15) via the method of SQLS using Exchangeable(ρj)⊗AR1(α)
working correlation structure for correlation within body system j, j = 1, 2 and for common correlation over time.
Standard 95% Confidence Interval
Model Parameter Estimate Error z-value p-value Lower Upper
Intercept -1.683 0.045 -37.08 < 0.001 -1.772 -1.594
Treatment 0.358 0.060 6.01 < 0.001 0.241 0.474
(13) Exchangeable(ρ1) 0.244
Exchangeable(ρ2) 0.200
AR1(α) 0.117
Intercept -1.562 0.089 -17.54 < 0.001 -1.737 -1.388
AE11 -0.439 0.128 -3.43 0.001 -0.690 -0.188
AE12 0.259 0.129 2.01 0.045 0.006 0.512
AE13 -0.174 0.138 -1.27 0.206 -0.446 0.096
AE21 -0.514 0.179 -2.87 0.004 -0.865 -0.163
Treatment 0.298 0.124 2.41 0.016 0.056 0.541
(14) AE11 × Treatment 0.165 0.176 0.94 0.349 -0.180 0.510
AE12 × Treatment -0.001 0.174 -0.01 0.993 -0.342 0.339
AE13 × Treatment 0.016 0.186 0.09 0.930 -0.349 0.381
AE21 × Treatment 0.234 0.225 1.04 0.298 -0.206 0.674
Exchangeable(ρ1) 0.255
Exchangeable(ρ2) 0.215
AR1(α) 0.100
Intercept -3.886 0.455 -8.54 < 0.001 -4.778 -2.994
AE11 -1.088 0.722 -1.51 0.132 -2.504 0.327
AE12 0.367 0.536 0.68 0.494 -0.683 1.416
AE13 0.001 0.617 0.00 0.999 -1.209 1.210
AE21 0.410 0.458 0.89 0.371 -0.489 1.308
Treatment 0.841 0.537 1.57 0.118 -0.212 1.893
Ontherapy 3.068 0.479 6.41 < 0.001 2.129 4.007
AE11 × Treatment 1.596 0.800 1.99 0.046 0.027 3.164
AE12 × Treatment 0.279 0.635 0.44 0.660 -0.965 1.524
AE13 × Treatment 0.289 0.721 0.40 0.689 -1.125 1.703
AE21 × Treatment 0.085 0.571 0.15 0.882 -1.033 1.203
(15) AE11 ×Ontherapy 0.658 0.747 0.88 0.379 -0.806 2.122
AE12 ×Ontherapy -0.116 0.555 -0.21 0.834 -1.204 0.971
AE13 ×Ontherapy -0.196 0.646 -0.30 0.762 -1.462 1.071
AE21 ×Ontherapy -1.021 0.495 -2.06 0.039 -1.990 -0.051
Ontherapy× Treatment -0.580 0.568 -1.02 0.308 -1.693 0.534
AE11 ×Ontherapy× Treatment -1.584 0.834 -1.90 0.058 -3.219 0.051
AE12 ×Ontherapy× Treatment -0.326 0.661 -0.49 0.622 -1.622 0.970
AE13 ×Ontherapy× Treatment -0.318 0.759 -0.42 0.676 -1.805 1.169
AE21 ×Ontherapy× Treatment 0.109 0.615 0.18 0.860 -1.097 1.135
Exchangeable(ρ1) 0.127
Exchangeable(ρ2) 0.112
AR1(α) 0.012
log(µijkl) = β0 + β1AEi11l + β2AEi12l
+ β3AEi13l + β4AEi21l + β5trti
+ β6(AEi11l × trti) + β7(AEi12l × trti)
+ β8(AEi13l × trti) + β9(AEi21l × trti)
(14)
where AEijkl = 1 if the ith subject experienced the kth AE in the jth body system at time l;
and = 0 otherwise; and AEijkl × trti is the interaction term between AEijkl and trti. Lastly,
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we may also investigate whether the number of AEs differ during the on-therapy period vs.
the follow-up period by fitting the following model:
log(µijkl) = β0 + β1AEi11l + β2AEi12l + β3AEi13l
+ β4AEi21l + β5trti + β6Ontherapyijk
+ β7(AEi11l × trti) + β8(AEi12l × trti)
+ β9(AEi13l × trti) + β10(AEi21l × trti)
+ β11(AEi11l ×Ontherapyijk)
+ β12(AEi12l ×Ontherapyijk)
+ β13(AEi13l ×Ontherapyijk)
+ β14(AEi21l ×Ontherapyijk)
+ β15(Ontherapyijk × trti)
+ β12(AEi11l ×Ontherapyijk × trti)
+ β13(AEi12l ×Ontherapyijk × trti)
+ β14(AEi13l ×Ontherapyijk × trti)
+ β15(AEi21l ×Ontherapyijk × trti)
(15)
where Ontherapyijk = 1 if the ith subject experienced the kth AE in the jth body system
during the on-therapy period; 0 otherwise.
As in a GEE analysis, misspecification of the working correlation structure may only
affect the efficiency of estimation of the regression parameter β, but not the consistency of
βˆ. Consequently, the estimates of the correlation parameters are mainly used to improve
efficiency, rather than to make formal inferences regarding the association parameters.
Table 4 summarizes the model fit for models (13), (14), and (15) via SQLS using the KP
working correlation structure Exchangeable(ρj)⊗AR1(α). Model (13) shows a significant
overall treatment effect (p-value < 0.001) which can be interpreted as follows: The overall
expected number of AEs for the treatment arm is exp(0.358) = 1.43 times higher than that
for the control arm (95% CI: 1.27 ∼ 1.61).
Model (14) is one of the most important models to answer the primary goal of the AE
analysis. In this model, we are mainly interested in the two-way interaction terms since the
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significance of an interaction term indicates that there is a difference in the number of AEs
for the treatment and the control arms, given the adverse event AEij. For example, from
Model (14), the expected difference in log of the number of AEs for the treatment vs. the
control arms with regards to AE11 can by computed as
log
(
µijkl|AEi11l = 1, trti = 1
µijkl|AEi11l = 1, trti = 0
)
= β5trti + β6(AEi11l × trti) (16)
while holding other variables constant. From Table 4, none of the interaction terms are
significant at a 5% significance level. Therefore, we may conclude that there is no statistically
strong evidence (or signal) that the number of AEs are different for two groups with respect
to each type of AE.
Lastly, Model (15) can be used to further explore the three-way interactions between each
type of AE, treatment, and on-therapy indicator variables. The expected difference in log of
the number of AEs for the treatment vs. the control arms during the on-therapy period with
regards to AE11 can by computed as
log
(
µijkl|AEi11l = 1,Ontherapyi = 1, trti = 1
µijkl|AEi11l = 1,Ontherapyi = 1, trti = 0
)
= β5trti + β7(AEi11l × trti) + β11(Ontherapyijk × trti)
+ β12(AEi11l ×Ontherapyijk × trti) (17)
while holding other variables constant. Similarly, for the follow-up period, the expected
difference in log of the number of AEs is given by
log
(
µijkl|AEi11l = 1,Ontherapyi = 0, trti = 1
µijkl|AEi11l = 1,Ontherapyi = 0, trti = 0
)
= β5trti + β7(AEi11l × trti) (18)
while holding other variables constant.
From Table 4, only the three-way interaction with respect to AE11, i.e. βˆ12 in Model
(15), is marginally significant at a 5% significance level (p-values = 0.058). Using (17) and
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(18), this suggests that the expected number of AEs for AE11 in the treatment arms is
exp(0.841 + 1.596 − 0.580 − 1.584) = 1.31 times greater than that that in the control arm
during the on-therapy period whiles it is exp(0.841 + 1.596) = 11.4 times greater during the
follow-up period. This can also be visually checked from Figure 1, where the number of AEs
for the treatment arm is much greater than in the control arm during the follow-up period,
i.e. after the 2nd week.
5. Discussion
We described various regression strategies to model multiple longitudinal AEs data via
the method of SQLS using the Exchangeable(ρj)⊗AR1(α) working correlation structure.
In particular, we allow a different correlation parameter ρj for each body system j assuming
the Exchangeable structure, and a common correlation parameter α for correlation over time
assuming the AR1 structure for all subjects. Consequently, SQLS fits a marginal model by
borrowing information across subjects, within each subject as well as across AEs within each
body system. This is one of the main advantages over conventional univariate methods such
as the χ2 test of independence, and the Fisher’s exact test. In addition, our approach takes
the number and type of AEs per subject over time into account, while application of the
Fisher’s exact test reduces the longitudinal follow-up information on each subject to whether
or not they had a particular type of AE during the follow-up period.
As shown in the analysis of the Wyeth safety data in §4, SQLS regression models (13),
(14), and (15) lead to a better understanding of the data by exploring the overall treatment
effect, the two-way, and three-way interactions among factors that are of interest to the
investigator(s) and/or regulatory agencies. These models allow useful interpretations that
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may better characterize the difference between the treatment vs. the control arms with
respect to each type of AE. A regression model may also adjust for the number of doses if
this information is available in the raw data, e.g. higher doses may lead to more AEs and
vice versa.
We have also developed a user-written SAS macro %QLS version 2 for fitting SQLS regres-
sion models for continuous, binary, and count multivariate (unbalanced) longitudinal data
using the Exchangeable(ρj)⊗AR1(α) working correlation structure. Our macro is available
for download from http://www.cceb.upenn.edu/~sratclif/QLSproject.html. (See Kim
and Shults (2008) for a detailed description and demonstration of the software).
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